Observed and expected progression and standardized incidence rates among 213 patients with IgM monoclonal gammopathy of undetermined significance
Disease progression . | Observed . | Expected* . | SIR . | 95% CI . |
|---|---|---|---|---|
| Non-Hodgkin lymphoma | 17 | 1.1 | 14.8 | 8.6-23.7 |
| Amyloidosis | 3 | 0.18 | 16.3 | 3.4-47.5 |
| Macroglobulinemia | 6 | 0.02 | 262 | 96.0-569.5 |
| Chronic lymphocytic leukemia | 3 | 0.53 | 5.7 | 1.2-16.5 |
| Total group | 29 | 1.83 | 15.9 | 11.0-22.8 |
Disease progression . | Observed . | Expected* . | SIR . | 95% CI . |
|---|---|---|---|---|
| Non-Hodgkin lymphoma | 17 | 1.1 | 14.8 | 8.6-23.7 |
| Amyloidosis | 3 | 0.18 | 16.3 | 3.4-47.5 |
| Macroglobulinemia | 6 | 0.02 | 262 | 96.0-569.5 |
| Chronic lymphocytic leukemia | 3 | 0.53 | 5.7 | 1.2-16.5 |
| Total group | 29 | 1.83 | 15.9 | 11.0-22.8 |
MGUS was diagnosed between 1960 and 1994 in patients in southeastern Minnesota.
SIR indicates standardized incidence rate; 95% CI, 95% confidence interval.
Iowa SEER Registry.